Lukang Pharma has launched two new products: Tulathromycin and Levodopa
Shandong Lukang Pharmaceutical Co., Ltd is a leading bio-pharmaceutical enterprise in China.
Shandong Lukang Pharma specializes in the supply of APIs, finished products and the general undertaking of CMO business. Recently, Lukang Pharma has launched two new products, Tulathromycin and Levodopa, and are working on many more.
Established in 1966, Lukang Pharma engaged in bio-pharmaceutical business involves API, human drugs, veterinary drugs and biopesticides.
- API such as Tylosin and Spectinomycin series are widely praised worldwide
- Human drugs cover antibiotics, antidiabetic, antiviral drug, cardio-cerebrovascular drug, neurodegenerative drug and so on
- Biopesticide: Bacillus Thuringiensis, Spinosad (upcoming), Gibberellin
- Undertake CMO and CDMO business.
Why choose Lukang Pharma:
- Sound quality management system, 56 years consistent good quality
- Our workshops take the lead through the ISO 9001, ISO 14001, ISO 45001 system certification.
- Strict regulatory compliance and continual improvement
- High GMP management system such as U.S. cGMP, EU GMP and ICH Q7, as well as Chinese GMP, with all products certified by GMP
- Complete EHS system and high-tech facilities
- Strong production capacity, perfect equipment, advanced techniques, and complete quality supervision system
- 2.7 square kilometers production parks, with over 6000 employees
- API annual output: 20000+tonnes including Fermentation and Synthesis
- Human Drug annual output: 8+billion capsules, 2+billion powder-injections, 1.5+billion tablets
- 3 R&D centres and 5 pilot platforms throughout the country.
Products:
Lukang Pharma has more than 500 types of products, which are of human, veterinary, and agricultural use.
Our new products: Tulathromycin (GMP+DMF)/ LEVODOPA (EP/USP).
Our complete product catalogue
For more information, please contact us at [email protected] or visit our website www.lkpc.com.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance